ES2531115T3 - Combinaciones de clados de RrgB neumocócicos - Google Patents
Combinaciones de clados de RrgB neumocócicos Download PDFInfo
- Publication number
- ES2531115T3 ES2531115T3 ES10723798T ES10723798T ES2531115T3 ES 2531115 T3 ES2531115 T3 ES 2531115T3 ES 10723798 T ES10723798 T ES 10723798T ES 10723798 T ES10723798 T ES 10723798T ES 2531115 T3 ES2531115 T3 ES 2531115T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- acid sequence
- amino acid
- pneumococcal
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Una composición inmunogénica que comprende al menos dos de: (a) un primer polipéptido que comprende una primera secuencia de aminoácidos, en el que la primera secuencia de aminoácidos comprende una secuencia de aminoácidos (i) que tiene al menos el 90 % de identidad de secuencias con SEC ID Nº: 1 y/o (ii) que consiste en un fragmento de al menos 7 aminoácidos contiguos de SEC ID Nº: 1, y que comprende un epítope de SEC ID Nº: 1; (b) un segundo polipéptido, que comprende una segunda secuencia de aminoácidos, en el que la segunda secuencia de aminoácidos comprende una secuencia de aminoácidos (i) que tiene al menos el 90 % de identidad de secuencias con SEC ID Nº: 2 y/o (ii) que consiste en un fragmento de al menos 7 aminoácidos contiguos de SEC ID Nº: 2, y que comprende un epítope de SEC ID Nº: 2; y/o (c) un tercer polipéptido, que comprende una tercera secuencia de aminoácidos, en el que la tercera secuencia de aminoácidos comprende una secuencia de aminoácidos (i) que tiene al menos el 90 % de identidad de secuencias con SEC ID Nº: 3 y/o (ii) que consiste en un fragmento de al menos 7 aminoácidos contiguos de SEC ID Nº: 3, y que comprende un epítope de SEC ID Nº: 3.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21762909P | 2009-06-01 | 2009-06-01 | |
| US25442609P | 2009-10-23 | 2009-10-23 | |
| US31420310P | 2010-03-16 | 2010-03-16 | |
| US31892610P | 2010-03-30 | 2010-03-30 | |
| PCT/IB2010/052445 WO2010140119A1 (en) | 2009-06-01 | 2010-06-01 | COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2531115T3 true ES2531115T3 (es) | 2015-03-10 |
Family
ID=42557471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10723798T Active ES2531115T3 (es) | 2009-06-01 | 2010-06-01 | Combinaciones de clados de RrgB neumocócicos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8609106B2 (es) |
| EP (1) | EP2437777B1 (es) |
| JP (2) | JP6008741B2 (es) |
| KR (1) | KR20120035168A (es) |
| CN (1) | CN102481354A (es) |
| AU (1) | AU2010255356A1 (es) |
| BR (1) | BRPI1011857A2 (es) |
| CA (1) | CA2764022A1 (es) |
| CO (1) | CO6470864A2 (es) |
| ES (1) | ES2531115T3 (es) |
| IL (1) | IL216696A0 (es) |
| MX (1) | MX2011012854A (es) |
| RU (1) | RU2011154363A (es) |
| SG (1) | SG176285A1 (es) |
| WO (1) | WO2010140119A1 (es) |
| ZA (1) | ZA201109046B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG178954A1 (en) | 2009-09-02 | 2012-04-27 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| CA2773637A1 (en) * | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| CN103313725B (zh) | 2010-09-01 | 2016-06-29 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| WO2012072769A1 (en) * | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| US9618508B2 (en) | 2010-12-14 | 2017-04-11 | Glaxosmithkline Biologicals Sa | Flow cytometry analysis of materials adsorbed to metal salts |
| KR20140026392A (ko) | 2011-03-02 | 2014-03-05 | 노파르티스 아게 | 저용량의 항원 및/또는 보조제를 갖는 조합 백신 |
| US20140072622A1 (en) | 2011-05-17 | 2014-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| LT2822947T (lt) | 2012-03-07 | 2016-10-10 | Glaxosmithkline Biologicals Sa | Tlr7 agonisto arginino druskos |
| EP2822586A1 (en) | 2012-03-07 | 2015-01-14 | Novartis AG | Adjuvanted formulations of streptococcus pneumoniae antigens |
| AU2013229432A1 (en) | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US20010016200A1 (en) * | 1998-04-23 | 2001-08-23 | Briles David E. | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
| AU2005243730B2 (en) * | 2004-04-12 | 2010-05-27 | Genvec, Inc. | Method of using adenoviral vectors to induce an immune response |
| US20090317420A1 (en) * | 2004-07-29 | 2009-12-24 | Chiron Corporation | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| EP1845376A4 (en) * | 2005-01-28 | 2008-07-09 | Shionogi & Co | QUANTITATIVE MEASURING PROCEDURE FOR RECOMBINANT PROTEIN |
| WO2007116322A2 (en) * | 2006-02-17 | 2007-10-18 | Novartis Ag | Purification of bacterial antigens |
| EP2063911A2 (en) * | 2006-07-26 | 2009-06-03 | Novartis Ag | Immunogenic compositions for gram positive bacteria |
| CN101553252A (zh) * | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| GB0714963D0 (en) * | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| JP5623910B2 (ja) * | 2007-11-02 | 2014-11-12 | ザ ジョンズ ホプキンス ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ | ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法 |
-
2010
- 2010-06-01 ES ES10723798T patent/ES2531115T3/es active Active
- 2010-06-01 KR KR1020117031617A patent/KR20120035168A/ko not_active Withdrawn
- 2010-06-01 JP JP2012513718A patent/JP6008741B2/ja not_active Expired - Fee Related
- 2010-06-01 MX MX2011012854A patent/MX2011012854A/es active IP Right Grant
- 2010-06-01 EP EP10723798.4A patent/EP2437777B1/en not_active Not-in-force
- 2010-06-01 BR BRPI1011857A patent/BRPI1011857A2/pt not_active IP Right Cessation
- 2010-06-01 CN CN2010800310544A patent/CN102481354A/zh active Pending
- 2010-06-01 AU AU2010255356A patent/AU2010255356A1/en not_active Abandoned
- 2010-06-01 US US12/791,186 patent/US8609106B2/en not_active Expired - Fee Related
- 2010-06-01 CA CA2764022A patent/CA2764022A1/en not_active Abandoned
- 2010-06-01 SG SG2011088275A patent/SG176285A1/en unknown
- 2010-06-01 US US13/375,759 patent/US20120076814A1/en not_active Abandoned
- 2010-06-01 RU RU2011154363/10A patent/RU2011154363A/ru not_active Application Discontinuation
- 2010-06-01 WO PCT/IB2010/052445 patent/WO2010140119A1/en not_active Ceased
-
2011
- 2011-11-30 IL IL216696A patent/IL216696A0/en unknown
- 2011-12-05 CO CO11167166A patent/CO6470864A2/es not_active Application Discontinuation
- 2011-12-08 ZA ZA2011/09046A patent/ZA201109046B/en unknown
-
2015
- 2015-09-04 JP JP2015174523A patent/JP2015227376A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2437777B1 (en) | 2014-09-17 |
| CN102481354A (zh) | 2012-05-30 |
| EP2437777A1 (en) | 2012-04-11 |
| RU2011154363A (ru) | 2013-07-20 |
| IL216696A0 (en) | 2012-02-29 |
| ZA201109046B (en) | 2013-05-29 |
| US20120076814A1 (en) | 2012-03-29 |
| JP2012528848A (ja) | 2012-11-15 |
| CA2764022A1 (en) | 2010-12-09 |
| WO2010140119A1 (en) | 2010-12-09 |
| AU2010255356A1 (en) | 2011-12-22 |
| MX2011012854A (es) | 2011-12-16 |
| CO6470864A2 (es) | 2012-06-29 |
| US20110020385A1 (en) | 2011-01-27 |
| JP6008741B2 (ja) | 2016-10-19 |
| SG176285A1 (en) | 2012-01-30 |
| KR20120035168A (ko) | 2012-04-13 |
| US8609106B2 (en) | 2013-12-17 |
| BRPI1011857A2 (pt) | 2016-03-29 |
| JP2015227376A (ja) | 2015-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2531115T3 (es) | Combinaciones de clados de RrgB neumocócicos | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| CY1122178T1 (el) | Πολυπεπτιδια | |
| ES2542853T3 (es) | Método para tratar miastenia grave | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| EA201270517A1 (ru) | Микобактериальные вакцины | |
| ES2668967T3 (es) | Inmunógenos de Escherichia coli con solubilidad mejorada | |
| ES2586418T3 (es) | Vacuna de proteína de fusión | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| AR085167A1 (es) | Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| ES2691539T3 (es) | Luciferasas de Oplophorus sintéticas con mayor emisión de luz | |
| EP2865387A3 (en) | Priming of an immune response | |
| ES2530777T3 (es) | Vacunas peptídicas para cánceres que expresan antígenos asociados a tumores | |
| CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
| UA110806C2 (uk) | Мікобактеріальна антигенна композиція | |
| NZ600690A (en) | Fkbp-l and uses thereof | |
| EA201000327A1 (ru) | Белок | |
| PE20121685A1 (es) | Antigeno ndv recombinante y usos del mismo | |
| AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| MX2016006277A (es) | Secuencia de endolisina kz144 modificada. |